Vermillion, Inc. (VRML) - NASDAQ
  • Yesterday, 11:00 AM
    | Yesterday, 11:00 AM | 3 Comments
  • Thu, Jul. 14, 12:46 PM
    | Thu, Jul. 14, 12:46 PM | 12 Comments
  • Thu, Jul. 14, 11:00 AM
    | Thu, Jul. 14, 11:00 AM | 2 Comments
  • Mon, Jun. 27, 12:51 PM
    | Mon, Jun. 27, 12:51 PM | 4 Comments
  • Mon, May 16, 4:03 PM
    • Vermillion (NASDAQ:VRML): Q1 EPS of -$0.09 in-line.
    • Revenue of $0.5M (-47.4% Y/Y) beats by $0.1M.
    • Press Release
    | Mon, May 16, 4:03 PM
  • Thu, Mar. 24, 9:34 AM
    • Vermillion (VRML) Q4 results: Revenues: $0.4M (-75.0%); R&D Expense: $0.9M (-25.0%); SG&A: $4.02M (+1.5%); Net Loss: ($5M) (-22.0%); Loss Per Share: ($0.10) (-9.1%).
    • FY2015 results: Revenues: $2.2M (-12.0%); R&D Expense: $3.8M (-19.1%); SG&A: $15.4M (-2.5%); Net Loss: ($19.1M) (+0.5%); Loss Per Share: ($0.41) (+22.6%); Quick Assets: $18.6M (-19.1%).
    • No guidance given.
    | Thu, Mar. 24, 9:34 AM
  • Thu, Mar. 24, 8:04 AM
    • Vermillion (NASDAQ:VRML): Q4 EPS of -$0.10 beats by $0.01.
    • Revenue of $0.36M (-77.1% Y/Y) misses by $0.04M.
    • Press Release
    | Thu, Mar. 24, 8:04 AM
  • Mon, Mar. 21, 9:57 AM
    • Vermillion (VRML +3.8%) receives 510(k) clearance for Overa, its second-generation test to OVA1, for determining ovarian cancer risk, in conjunction clinical and imaging assessment, prior to planned surgery for women with a pelvic mass.
    • Overa replaces two of the five biomarkers in OVA1 with HE4 (human epididymis protein 4) and FSH (follicle-stimulating hormone) which improves specificity (detecting true negatives/reducing the number of false positives) while reducing the need for doctors to determine menopausal status when interpreting the test.
    • The test is performed on Roche's Cobas 6000 series automated analyzer.
    | Mon, Mar. 21, 9:57 AM
  • Nov. 12, 2015, 10:14 AM
    • Vermillion (VRML -0.5%) Q3 results: Revenues: $0.33M (+3.1%); SG&A: $4.7M (-11.3%); Net Loss: ($5.1M) (+8.9%); Loss Per Share: ($0.10) (+37.5%); Quick Assets: $24M (+4.3%).
    • No guidance given.
    | Nov. 12, 2015, 10:14 AM
  • Nov. 12, 2015, 8:04 AM
    • Vermillion (NASDAQ:VRML): Q3 EPS of -$0.10 beats by $0.01.
    • Revenue of $0.33M (+3.1% Y/Y) misses by $0.45M.
    | Nov. 12, 2015, 8:04 AM
  • Aug. 13, 2015, 9:45 AM
    • Vermillion (VRML +0.5%) Q2 results: Revenues: $0.5M (+66.7%); COGS: $0.6M (+566.7%); R&D Expense: $0.9M (-18.2%); SG&A: $3.9M (-17.0%); Net Loss: ($4.8M) (+14.3%); Loss Per Share: ($0.11) (+26.7%); Quick Assets: $10.9M (-52.6%).
    • No guidance given.
    | Aug. 13, 2015, 9:45 AM
  • Aug. 13, 2015, 9:10 AM
    • Vermillion (NASDAQ:VRML): Q2 EPS of -$0.11 misses by $0.02.
    • Revenue of $0.54M (+68.8% Y/Y) misses by $0.61M.
    | Aug. 13, 2015, 9:10 AM
  • Jul. 17, 2015, 12:53 PM
    • Vermillion (VRML +6.1%) closes its public offering of 9,602,500 shares of common stock at $1.96 per share. Net proceeds of $17.5M will fund commercialization activities, bioinformatics platform enhancements, portfolio expansion and general corporate purposes.
    | Jul. 17, 2015, 12:53 PM
  • May 11, 2015, 4:28 PM
    • Vermillion (NASDAQ:VRML): Q1 EPS of -$0.10 in-line.
    • Revenue of $0.95M (+216.7% Y/Y) beats by $0.15M.
    | May 11, 2015, 4:28 PM
  • Mar. 25, 2015, 8:16 AM
    • Vermillion (VRML +1%) Q4 results: Revenues: $1.57M (-1.3%); COGS: $0.5M (+614.3%); R&D Expense: $1.2M (+20.0%); SG&A: $4M (+73.9%); Net Loss: ($4.1M) (-127.8%); Loss Per Share: ($0.11) (-57.1%).
    • FY2014 results: Revenues: $2.5M (-3.8%); COGS: $1.2M (+500.0%); R&D Expense: $4.7M (+80.8%); SG&A: $15.8M (+81.6%); Net Loss: ($19.2M) (-118.2%); Loss Per Share: ($0.53) (-26.2%); Quick Assets: $23M (-22.0%).
    • No guidance given.
    | Mar. 25, 2015, 8:16 AM
  • Mar. 25, 2015, 8:03 AM
    • Vermillion (NASDAQ:VRML): Q4 EPS of -$0.11
    • Revenue of $1.57M (-1.3% Y/Y)
    | Mar. 25, 2015, 8:03 AM
Company Description
Vermillion, Inc. provides diagnostic service and bio-analytic solutions. It also provides innovative methods to detect, monitor and manage the treatment of gynecologic disease-both benign and malignant cancers as well as other gynecologic diseases. It develops and commercializes high-value,... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: United States